These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 17620747)

  • 1. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean.
    Wolf LL; Ricketts P; Freedberg KA; Williams-Roberts H; Hirschhorn LR; Allen-Ferdinand K; Rodriguez WR; Divi N; Wong MT; Losina E
    J Acquir Immune Defic Syndr; 2007 Dec; 46(4):463-71. PubMed ID: 18077836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
    Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
    AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
    Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
    AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.
    Bender MA; Kumarasamy N; Mayer KH; Wang B; Walensky RP; Flanigan T; Schackman BR; Scott CA; Lu Z; Freedberg KA
    Clin Infect Dis; 2010 Feb; 50(3):416-25. PubMed ID: 20043752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
    Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
    Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
    Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
    PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults.
    Schackman BR; Goldie SJ; Weinstein MC; Losina E; Zhang H; Freedberg KA
    Am J Public Health; 2001 Sep; 91(9):1456-63. PubMed ID: 11527782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis.
    Walensky RP; Wood R; Ciaranello AL; Paltiel AD; Lorenzana SB; Anglaret X; Stoler AW; Freedberg KA;
    PLoS Med; 2010 Dec; 7(12):e1000382. PubMed ID: 21209794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
    Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA;
    AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
    Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
    N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
    Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
    AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India.
    Zheng A; Kumarasamy N; Huang M; Paltiel AD; Mayer KH; Rewari BB; Walensky RP; Freedberg KA
    J Int AIDS Soc; 2018 Mar; 21(3):e25085. PubMed ID: 29603882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India.
    Venkatesh KK; Becker JE; Kumarasamy N; Nakamura YM; Mayer KH; Losina E; Swaminathan S; Flanigan TP; Walensky RP; Freedberg KA
    PLoS One; 2013; 8(5):e64604. PubMed ID: 23741348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti.
    Koenig SP; Bang H; Severe P; Jean Juste MA; Ambroise A; Edwards A; Hippolyte J; Fitzgerald DW; McGreevy J; Riviere C; Marcelin S; Secours R; Johnson WD; Pape JW; Schackman BR
    PLoS Med; 2011 Sep; 8(9):e1001095. PubMed ID: 21949643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India.
    Uhler LM; Kumarasamy N; Mayer KH; Saxena A; Losina E; Muniyandi M; Stoler AW; Lu Z; Walensky RP; Flanigan TP; Bender MA; Freedberg KA; Swaminathan S;
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20862279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.